Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HCV-796 + peginterferon alfa-2b + ribavirin
- Development stage
- Discontinued
- Lead developer
- Takeda
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous
01
Overview
This combination is an experimental antiviral regimen consisting of **HCV-796** (a selective small molecule inhibitor of the hepatitis C virus RNA-dependent RNA polymerase NS5B), **peginterferon alfa-2b** (a pegylated form of interferon alfa-2b with immune-modulating and antiviral actions), and **ribavirin** (a broad-spectrum antiviral nucleoside analog). HCV-796 is designed to directly inhibit NS5B polymerase activity, blocking viral RNA replication. Peginterferon alfa-2b acts by stimulating immune responses and interfering with viral replication, while ribavirin increases viral mutagenesis leading to production of non-infectious particles and exerts weak direct inhibition of viral replication. The combination was researched primarily as a therapy for chronic hepatitis C virus (HCV) infection.
- Other names
- peginterferon alpha-2bribavirin
02
Targets
NS5B (Hepatitis C virus non-structural protein 5B (NS5B) RNA-dependent RNA polymerase)IFNAR (Immune system modulation via type I interferon receptor)HCV RNA (Hepatitis C virus RNA)
Beyond the preview
Go deeper on HCV-796 + peginterferon alfa-2b + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HCV-796 + peginterferon alfa-2b + ribavirin.